Skip to main navigation
 
Search
Zentalis
Top Navigation
  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisory Board
      • Partners & Collaborations
    • Contact Us
  • Our Pipeline
    • Pipeline
      • ZN-c3
      • ZN-d5
    • Clinical Trials
  • Our Approach
    • Integrated Discovery Engine
    • Supporting Publications
  • Investors & Media
    • Investor Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Scientific Advisory Committee
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Careers
    • Why Zentalis?
    • Job Opportunities

Investors & Media

Press Releases

Mar 01, 2023
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
Feb 13, 2023
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
Feb 01, 2023
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 01, 2023
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Jan 03, 2023
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors/Media

  • Investor Home
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Scientific Advisory Committee
    • Committee Composition
  • Investor Resources
    • Investor FAQs
    • Investor Contact
    • Email Alerts

Investor Contact

Adam Levy
Senior Vice President,
Investor Relations
alevy@zentalis.com

Alexandra Roy
Solebury Strategic Communications
aroy@soleburystrat.com

Media Contact

Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com

“The sun is but a morning star.”

Zentalis Logo

Corporate Office

1359 Broadway
Suite 1710
New York, NY 10018

Science Center

10275 Science Center Dr.
Suite 200
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com
Footer
  • Privacy Policy
  • Terms of Use
  • Expanded Access Policy
  • Site Map

Copyright © 2023 Zentalis Pharmaceuticals. All Rights Reserved.